BACKGROUND: Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD). AIMS: To evaluate the efficacy and safety of adalimumab on a nationwide clinical setting. METHODS: We used the Scottish Society of Gastroenterology network to identify and follow up the clinical outcomes of patients with CD treated with adalimumab over a 4-year period (2004-2008). RESULTS: A total of 98 patients received adalimumab - 100.5 patient follow-up years were recorded (64.3% females; median age at diagnosis of 20.7 years; 88.8% treated with 80/40 mg induction regimen. Eighty eight (89.8%) had previous infliximab with 29 (32.9%) primary nonresponders; 32 (32.6%) were corticosteroid-dependent; 47 (47.9%) were intolerant/resistant to most immunosuppressive therapies (two or more). In all, 60% of patients were in clinical remission at 1-year follow-up, with 30% and 55% requiring dose escalation to weekly therapy at 1-and 2-year follow-up respectively. Overall, 29 (29.6%) patients developed complications with eight nonfatal serious (8.2%) adverse events and 2 (2.0%) case fatalities (sepsis following perforation and disseminated colorectal cancer, respectively). CONCLUSIONS: Adalimumab is efficacious in severe and refractory CD in the clinical setting, although there remain significant therapy- and disease-related risks of serious complications.
BACKGROUND:Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD). AIMS: To evaluate the efficacy and safety of adalimumab on a nationwide clinical setting. METHODS: We used the Scottish Society of Gastroenterology network to identify and follow up the clinical outcomes of patients with CD treated with adalimumab over a 4-year period (2004-2008). RESULTS: A total of 98 patients received adalimumab - 100.5 patient follow-up years were recorded (64.3% females; median age at diagnosis of 20.7 years; 88.8% treated with 80/40 mg induction regimen. Eighty eight (89.8%) had previous infliximab with 29 (32.9%) primary nonresponders; 32 (32.6%) were corticosteroid-dependent; 47 (47.9%) were intolerant/resistant to most immunosuppressive therapies (two or more). In all, 60% of patients were in clinical remission at 1-year follow-up, with 30% and 55% requiring dose escalation to weekly therapy at 1-and 2-year follow-up respectively. Overall, 29 (29.6%) patients developed complications with eight nonfatal serious (8.2%) adverse events and 2 (2.0%) case fatalities (sepsis following perforation and disseminated colorectal cancer, respectively). CONCLUSIONS:Adalimumab is efficacious in severe and refractory CD in the clinical setting, although there remain significant therapy- and disease-related risks of serious complications.
Authors: Frank I Scott; Mark T Osterman; Ryan A McConnell; Monica Lorusso; Faten Aberra; Caroline Kerner; Gary R Lichtenstein; James D Lewis Journal: Inflamm Bowel Dis Date: 2013-11 Impact factor: 5.325
Authors: Maurizio Benucci; Mariangela Manfredi; Sergio Testi; Maria L Iorno; Maurizio Valentini; Francesca Soldaini; Paolo Campi Journal: J Med Case Rep Date: 2011-04-19
Authors: Jason P Gordon; Phil C McEwan; Andy Maguire; Daniel M Sugrue; Jorge Puelles Journal: Eur J Gastroenterol Hepatol Date: 2015-07 Impact factor: 2.566
Authors: Oliver Zimmermann; Jörg M Homann; Anna Bangert; Anna-Maria Müller; Georgi Hristov; Stefan Goeser; Juliane M Wiehe; Stefan Zittrich; Wolfgang Rottbauer; Jan Torzewski; Gabriele Pfitzer; Hugo A Katus; Ziya Kaya Journal: J Am Heart Assoc Date: 2012-12-19 Impact factor: 5.501